Command Palette

Search for a command to run...

Clinical Trials · NCT01175473

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

CompletedPhase 2Liraglutide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Sanofi
Enrollment
148
Start date
Aug 2010
Locations
7 sites, Germany
Primary endpoint
Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28
View Liraglutide compound reference